On June 9, 2022 Shanghai I-Mab reported that it will alter its collaboration with Switzerland’s Ferring Pharma to develop olamkicept, a potential therapy for inflammatory bowel disease (Press release, I-Mab Biopharma, JUN 9, 2022, View Source [SID1234615863]). In 2016, I-Mab acquired rights to develop olamkicept. a selective interleukin-6 inhibitor, in Greater China and Korea. Now, Ferring will invest in the global development of olamkicept, while I-Mab will have an option to collaborate with Ferring in olamkicept’s global development at a pre-defined milestone. No details were given, though Ferring mal underwrite a China Phase III trial of olamkicept, and I-Mab will opt into global development later.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!